肾内科指南

订阅

MedSci主页 / 所有栏目 / 肾内科指南

2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理

2021-02-23 改善全球肾脏病预后组织 Kidney International (2021) 99, 559–569.

慢性肾脏病

2021年2月，改善全球肾脏病预后组织（KDIGO）发布了2021版慢性肾脏病（CKD）血压管理临床实践指南。该指南是对2012年版指南的更新，包括11项推荐和若干实践要点，主要适用于未接受透析的CK

中文标题：

2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理

英文标题：

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

发布机构：

改善全球肾脏病预后组织

发布日期：

2021-02-23

简要介绍：

2021年2月，改善全球肾脏病预后组织（KDIGO）发布了2021版慢性肾脏病（CKD）血压管理临床实践指南。该指南是对2012年版指南的更新，包括11项推荐和若干实践要点，主要适用于未接受透析的CKD患者。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=273891c0020e27f7, title=2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理, enTitle=KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease, guiderFrom=Kidney International (2021) 99, 559–569., authorId=0, author=, summary=2021年2月，改善全球肾脏病预后组织（KDIGO）发布了2021版慢性肾脏病（CKD）血压管理临床实践指南。该指南是对2012年版指南的更新，包括11项推荐和若干实践要点，主要适用于未接受透析的CK, cover=https://img.medsci.cn/2021325/1616684613324_2020535.jpg, journalId=0, articlesId=null, associationId=108, associationName=改善全球肾脏病预后组织, associationIntro=改善全球肾脏病预后组织(Kidney Disease: ImprovingGlobal Outcomes,KDIGO)是一个国际性的非营利性组织,旨在通过促进和协调世界范围内的大合作,整合已有的相关工作,制定出适用于慢性肾病患者的临床实践指南,并在世界不同地区加以推广,以改善全球肾病患者的预后。, copyright=0, guiderPublishedTime=Tue Feb 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年2月，改善全球肾脏病预后组织（KDIGO）发布了2021版慢性肾脏病（CKD）血压管理临床实践指南。该指南是对2012年版指南的更新，包括11项推荐和若干实践要点，主要适用于未接受透析的CKD患者。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2527, tagName=慢性肾脏病)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2527, guiderKeyword=慢性肾脏病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12436, appHits=690, showAppHits=0, pcHits=1836, showPcHits=11740, likes=6, shares=56, comments=43, approvalStatus=1, publishedTime=Thu Mar 25 23:31:11 CST 2021, publishedTimeString=2021-02-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Mar 25 23:03:43 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 07:11:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理.pdf)])
2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理.pdf
下载请点击：
评论区 (32)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1201074, encodeId=29f712010e47e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:05 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199395, encodeId=771911993950c, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:37:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187974, encodeId=32fc118e97467, content=英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Tue Jan 25 11:08:16 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178934, encodeId=4eea11e893435, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4bc6441444, createdName=ms9000002108190477, createdTime=Thu Dec 30 18:15:00 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082152, encodeId=ad201082152d7, content=这是中文版的还是英文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e19b1551932, createdName=hn29585994, createdTime=Mon Dec 20 17:05:21 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2022-03-09 ms9000001115066421

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1201074, encodeId=29f712010e47e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:05 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199395, encodeId=771911993950c, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:37:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187974, encodeId=32fc118e97467, content=英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Tue Jan 25 11:08:16 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178934, encodeId=4eea11e893435, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4bc6441444, createdName=ms9000002108190477, createdTime=Thu Dec 30 18:15:00 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082152, encodeId=ad201082152d7, content=这是中文版的还是英文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e19b1551932, createdName=hn29585994, createdTime=Mon Dec 20 17:05:21 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2022-03-04 ms2000001050457721

    我要积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1201074, encodeId=29f712010e47e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:05 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199395, encodeId=771911993950c, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:37:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187974, encodeId=32fc118e97467, content=英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Tue Jan 25 11:08:16 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178934, encodeId=4eea11e893435, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4bc6441444, createdName=ms9000002108190477, createdTime=Thu Dec 30 18:15:00 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082152, encodeId=ad201082152d7, content=这是中文版的还是英文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e19b1551932, createdName=hn29585994, createdTime=Mon Dec 20 17:05:21 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2022-01-25 ms9000001115066421

    英文版

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1201074, encodeId=29f712010e47e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:05 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199395, encodeId=771911993950c, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:37:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187974, encodeId=32fc118e97467, content=英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Tue Jan 25 11:08:16 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178934, encodeId=4eea11e893435, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4bc6441444, createdName=ms9000002108190477, createdTime=Thu Dec 30 18:15:00 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082152, encodeId=ad201082152d7, content=这是中文版的还是英文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e19b1551932, createdName=hn29585994, createdTime=Mon Dec 20 17:05:21 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2021-12-30 ms9000002108190477

    我要积分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1201074, encodeId=29f712010e47e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:05 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199395, encodeId=771911993950c, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3a6455137, createdName=ms2000001050457721, createdTime=Fri Mar 04 15:37:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187974, encodeId=32fc118e97467, content=英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Tue Jan 25 11:08:16 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178934, encodeId=4eea11e893435, content=我要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4bc6441444, createdName=ms9000002108190477, createdTime=Thu Dec 30 18:15:00 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082152, encodeId=ad201082152d7, content=这是中文版的还是英文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e19b1551932, createdName=hn29585994, createdTime=Mon Dec 20 17:05:21 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2021-12-20 hn29585994

    这是中文版的还是英文

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

NICE指南：新冠肺炎期间慢性肾脏病

国家卫生和护理研究所（NICE） · 2020-05-15

慢性肾脏病高钾血症风险评估及管理专家建议（2020版）

肾脏病相关专家小组（统称） · 2020-12-01

维生素D及其类似物在慢性肾脏病患者中应用的中国实践方案（2019版）

中国医师协会肾内科医师分会 · 2020-02-20

2020 营养和饮食学会/NKF临床实践指南：慢性肾脏病患者营养（概要）

美国营养与饮食学会(Academy of Nutrition and Dietetics) · 2020-11-03

2020 欧洲共识声明：G4-G5D期慢性肾脏病患者骨质疏松的诊断和管理

欧洲肾脏学会-欧洲透析和移植学会(ERA-EDTA,European Renal Association&ndash;European Dialysis and Transplant Association) · 2020-10-24

CKD所有阶段的患者疫苗接种实用指南

暂未更新 · 2020-05-01

拓展阅读

2015慢性肾脏病评估及管理临床实践指南解读——从 K/DOQI 到 KDIGO

国际肾脏病学会(ISN,International Society of Nephrology) · 2016-04-25

2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识（2015年更新版）

中国医师协会内分泌代谢科医师分会 · 2016-06-30

2015 NICE指南：慢性肾脏病：贫血管理（NG8）

暂未更新 · 2015-06-03

中国成人慢性肾脏病合并结核病管理专家共识

暂未更新 · 2016-11-30

慢性肾脏病筛查诊断及防治指南

肾脏病相关专家小组（统称） · 2017-01-30

HIV感染合并慢性肾脏病患者管理专家共识

中国感染病相关专家组（统称） · 2017-06-15